Analysts have clear opinions on RARX.

There are 1 analyst offering 12 month price targets for Ra Pharmaceuticals in the last 3 months. The average price target is $48.00 with a high forecast of $48.00 and a low forecast of $48.00. The average price target represents a 2.63% increase from the last price of $46.77.
Ra Pharmaceuticals, Inc. (RARX) is followed by 1 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Ra Pharmaceuticals, Inc.(RARX) do ?
Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The company’s product include RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. Ra Pharmaceuticals was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.

Ra Pharmaceuticals, Inc. (RARX) Insider Trades

Multiple company employees have indulged in significant insider trading. Ra Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Chief Medical Officer, Farzaneh-Far Ramin : S – Sale+OE(-$493,850) of RARX in the trading session of 2020-02-18.

See Remarks Ricardo Alonso : S – Sale(-$107,441) of RARX in the trading session of 2020-01-17.

Chief Medical Officer Farzaneh-Far Ramin : S – Sale+OE(-$497,441) of Ra Pharmaceuticals, Inc. in the trading session of 2020-01-15.

Looking for stocks just like RARX?

Based on Wall Street analyst research, several stocks are similar to RARX
They are:
– ELOX [Info can be found here: ]
– SESN [Info can be found here: ]
– ALXN [Info can be found here: ]